Myositis treatment applications encompass various autoimmune-related muscle inflammatory conditions. Targeted therapies specifically address the underlying immune dysfunction, providing personalized treatment options for patients. Advantages of these therapies include enhanced efficacy, reduced side effects, and improved symptom management. Additionally, early diagnosis facilitated by advancements in medical technology helps identify the specific myositis subtype, leading to timely and tailored treatment. The features of myositis treatment focus on modulating the immune response and promoting better disease control, offering patients a higher quality of life and improved long-term outcomes.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-myositis-treatment-market
Data Bridge Market Research analyses that the Global Myositis Treatment Market is valued at 493.15 million in 2022 and is expected to reach USD 696.57 million by 2030, registering a CAGR of 4.4% during the forecast period of 2023 to 2030. An increase in the number of myositis cases worldwide has driven the demand for effective treatments. The growing awareness and early diagnosis of myositis have contributed to the expansion of the treatment market.
Key Findings of the Study
The availability of targeted therapies is expected to drive the market's growth rate
Targeted therapies in myositis focus on modulating the immune response responsible for muscle inflammation. These treatments offer enhanced efficacy by precisely targeting the underlying autoimmune processes, reducing side effects, and improving patient outcomes. As personalized treatment options become available, patients experience better symptom management and disease control, leading to increased demand for these therapies in the myositis treatment market. The shift towards targeted therapies has revolutionized myositis management and significantly impacted market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Inclusion-Body Myositis, Polymyositis, Dermatomyositis, Others), Diagnosis (Muscle Biopsy, Electromyography, Myositis Specific Antibody Panel Blood Test, Genetic Testing, Others), Therapy Type (Exercise and Physiotherapy, Steroid Medication, Intravenous Immunoglobulin Therapy, Others), Route of Administration (Oral, Injectable and Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Corbus Pharmaceuticals Holdings, Inc (U.S.), CytRx Corporation (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), IDERA, Inc. (U.S.), Genentech, Inc (U.S.), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), GlaxoSmithKline plc. (India), Mallinckrodt (U.K.), Bausch Health Companies Inc.(Canada), Akorn Operating Company LLC (U.S.), Sanofi (France), Promega Corporation (U.S.), AstraZeneca (U.K.), and Amgen Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The myositis treatment market is segmented on the basis of type, diagnosis, therapy type, route of administration, end-user and distribution channel.
- On the basis of type, the market is segmented into polymyositis, dermatomyositis, inclusion body myositis (IBM), others. In 2023, polymyositis segment is expected to dominate the market with CAGR of 5.6% in the forecast period of 2023 to 2030 due to its higher prevalence of polymyositis compared to other subtypes.
In 2023, the polymyositis segment is expected to dominate the global myositis treatment market during the forecast period 2023 to 2030
In 2023, polymyositis is expected to dominate global myositis treatment market with highest CAGR of 5.6% in the forecast period of 2023 to 2030 as polymyositis accounts for a significant proportion of myositis cases, leading to a greater demand for specific treatments targeting this subtype. Healthcare providers focus on developing and offering targeted therapies for polymyositis patients, driving advancements in research and drug development. Additionally, as polymyositis can be a severe and chronic condition, patients often require long-term management and specialized care, further reinforcing the prominence of this segment in the myositis treatment market.
- On the basis of diagnosis, the market is segmented into muscle biopsy, electromyography, myositis specific antibody panel blood test, genetic testing, and others.
- On the basis of therapy type, the market is segmented into exercise and physiotherapy, steroid medication, intravenous immunoglobulin therapy, and others.
- On the basis of route of administration, the market is segmented into oral, injectable, and others.
- On the basis of end user, the market is segmented into hospitals, specialty clinics, homecare, others. In 2023, hospitals segment is expected to dominate the market with the CAGR of 6.4% in the forecast period of 2023 to 2030 due to its comprehensive and specialized medical care facilities.
- On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies, others. In 2030, hospital pharmacies segment is expected to dominate the market with CAGR of 6.5% in the forecast period of 2023 to 2030 as hospitals serve as primary treatment centers for myositis patients, providing access to specialized medical care and expertise.
In 2023, hospital pharmacies segment is expected to dominate global myositis treatment market during the forecast period 2023 to 2030
In 2023, hospital pharmacies are expected to dominate global myositis treatment market with highest CAGR of 6.5% in the forecast period of 2023 to 2030 as hospital pharmacies maintain a wide range of medications, including targeted therapies and immunosuppressive drugs, essential for managing myositis effectively. Additionally, hospital-based treatments facilitate close monitoring of patients' conditions, ensuring timely adjustments to medication regimens. Furthermore, the availability of in-patient care and emergency services in hospitals makes them the preferred choice for myositis treatment, contributing significantly to the segment's dominance in the market.
Major Players
Data Bridge Market Research recognizes the following companies as the major myositis treatment market players in Myositis treatment market are Corbus Pharmaceuticals Holdings, Inc (U.S.), CytRx Corporation (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), IDERA, Inc. (U.S.), Genentech, Inc (U.S.), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), GlaxoSmithKline plc. (India)
Regional Analysis
Geographically, the countries covered in the myositis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the myositis treatment market during the forecast period 2023 - 2030
In 2023, North America dominated the myositis treatment market as advanced medical facilities, specialized clinics, and experienced healthcare professionals, patients have access to comprehensive diagnostic tools and treatment options. The availability of cutting-edge therapies, including targeted treatments that address the autoimmune component of myositis, contributes to better disease management and improved patient outcomes. The combination of a robust healthcare system and a wide range of available treatments positions the region as a favorable destination for myositis patients seeking effective and comprehensive care.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030
In 2023, Asia-Pacific is expected to witness significant growth as countries invest in upgrading medical facilities, diagnostic capabilities, and specialized healthcare centers, and overall access to myositis treatment improves. The increasing geriatric population, being more susceptible to myositis, drives demand for effective therapies and personalized care. With better medical facilities and a growing pool of elderly patients, healthcare providers are prompted to offer advanced treatments and comprehensive management options, making the region a promising hub for myositis care and research.
For more detailed information about the myositis treatment market report, click here – https://www.databridgemarketresearch.com/reports/global-myositis-treatment-market
